Abstract
A series of 3H-imidazo [4,5-b] pyridines derivatives were designed and synthesized as selective mTOR inhibitors. The systematic optimization of the molecules resulted in the identification of two compounds 10d and 10n with nanomolar mTOR inhibitory activity and selectivity over PI3Kα. Besides, compounds 10d and 10n demonstrated attractive potency against human breast cancer cells (MCF-7) and human ovarian cancer cell (A2780).
Keywords:
3H-Imidazo [4,5-b] pyridine; Antitumor; Mammalian target of rapamycin; Synthesis; mTOR inhibitors.
Copyright © 2017 Elsevier Ltd. All rights reserved.
MeSH terms
-
Cell Line, Tumor
-
Cell Proliferation / drug effects
-
Dose-Response Relationship, Drug
-
Drug Design*
-
Humans
-
Imidazoles / chemical synthesis
-
Imidazoles / chemistry
-
Imidazoles / pharmacology*
-
Molecular Structure
-
Protein Kinase Inhibitors / chemical synthesis
-
Protein Kinase Inhibitors / chemistry
-
Protein Kinase Inhibitors / pharmacology*
-
Pyridines / chemical synthesis
-
Pyridines / chemistry
-
Pyridines / pharmacology*
-
Structure-Activity Relationship
-
TOR Serine-Threonine Kinases / antagonists & inhibitors*
Substances
-
Imidazoles
-
Protein Kinase Inhibitors
-
Pyridines
-
MTOR protein, human
-
TOR Serine-Threonine Kinases